Sensitive

Conversion from active surveillance to active treatment in prostate cancer

near LINC01101 · rs1404610

Where this position leads

What the study found

Who was studied 1,609 European ancestry cases, 3,613 European ancestry controls; replicated in 77 European ancestry cases, 348 European ancestry controls, 123 African ancestry cases, 273 African ancestry controls, 88 Asian ancestry cases, 149 Asian ancestry controls, 21 Latin American cases, 60 Latin American controls.

The effect Each copy of the G allele carried 3.74 times the odds of Conversion from active surveillance to active treatment in prostate cancer (95% confidence interval 2.47-5.67); p = 5 × 10⁻¹⁰.

How common The G allele had a frequency of about 1% in the people studied.

Where it sits Chromosome 2, band 2q14.2 — between genes, 66.8 kb from LINC01101.

What each result means

A/A No copy of the version the research linked to Conversion from active surveillance to active treatment in prostate cancer. This is the starting point the study compared everyone against.

A/G One copy of the version the research linked to Conversion from active surveillance to active treatment in prostate cancer. That is a smaller link than two copies.

G/G Two copies of the version the research linked to Conversion from active surveillance to active treatment in prostate cancer. That is the strongest link of the three results. A link in a study is not a diagnosis.

Source

Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment

Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S

and 85 more — show all

Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ Jr, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS

HGG advances · 2022 · PMID 34993496 · open access

Questions about rs1404610

What is rs1404610?

rs1404610 is a single position in the genome, in or near the near LINC01101 gene. Published research associates it with conversion from active surveillance to active treatment in prostate cancer. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

What conditions is rs1404610 linked to?

On MyGeneLog this position is linked to Prostate Cancer. The research behind each link, and its sources, are set out on that condition page.

Does having rs1404610 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs1404610 come from?

GWAS Catalog, HGG advances 2022, PMID:34993496. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

Quoting this page

Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.

Conversion from active surveillance to active treatment in prostate cancer (rs1404610). MyGeneLog™. https://www.mygenelog.com/variants/rs1404610

← See all variants